Peripheral venoarterial extracorporeal membrane oxygenation improves survival in myocardial infarction with cardiogenic shock  by Tang, Gilbert H.L. et al.
Case ReportsPeripheral venoarterial extracorporeal membrane oxygenation
improves survival in myocardial infarction with cardiogenic shockGilbert H. L. Tang, MD, MSc, Ramin Malekan, MD, Masashi Kai, MD, Steven L. Lansman, MD, PhD, and
David Spielvogel, MD, Valhalla, NYTABLE 1. Patient characteristics (n ¼ 21)
Characteristic Value
Age (y) 61  14
Women 7 (33%)
Hypertension 12 (57%)
Diabetes 9 (43%)
Hyperlipidemia 11 (52%)
Smoker 7 (33%)
Renal failure 1 (5%)
COPD 2 (10%)Despite early revascularization, cardiogenic shock compli-
cating acute myocardial infarction carries high mortality.
Intra-aortic balloon pump (IABP) support was recently
found to confer no mortality benefit over medical therapy
in the Intraaortic Balloon Pump in Cardiogenic Shock II
(IABP-SHOCK II) trial.1 This communication focuses on
our experience with venoarterial (VA) peripheral extracor-
poreal membrane oxygenation (pECMO) in patients with
acute myocardial infarction complicated by cardiogenic
shock.PVD 4 (19%)
TIA/stroke 2 (10%)
History of MI 16 (76%)
History of CHF 8 (38%)
Cardiogenic shock 21 (100%)
Previous PCI 11 (52%)
Previous CABG 4 (19%)
Ventricular tachycardia/fibrillation 11 (52%)
Cardiac arrest requiring resuscitation 10 (48%)
IABP or Impella support before ECMO 21 (100%)
Predicted mortality from APACHE4 score 38%  16%
Catheterization laboratory 45%  16%
Operating room 36%  16%
Data presented as mean  standard deviation or n (%). COPD, Chronic obstructive
pulmonary disease; PVD, peripheral vascular disease; TIA, transient ischemic attack;
MI, myocardial infarction; CHF, congestive heart failure; PCI, percutaneous coro-
nary intervention; IABP, intra-aortic balloon pump; ECMO, extracorporeal mem-
brane oxygenation; APACHE4, Acute Physiology and Chronic Health Evaluation
IV; CABG, coronary artery bypass grafting.CLINICAL SUMMARY
From January 2010 to August 2012, 60 consecutive
patients were referred to our institution with cardiogenic
shock and all underwent VA ECMO placement. Of the
60 patients, 21 had acute myocardial infarction compli-
cated by cardiogenic shock, defined as systolic blood
pressure less than 80 mm Hg, despite inotropic and/or
mechanical support. At presentation, all patients were
supported by an IABP or Impella 2.5 device (Abiomed,
Danvers, Mass). Their mean age was 61 years, 8 had
been resuscitated from cardiac arrest, and the Acute Phys-
iology and Chronic Health Evaluation IV scores indicated
a 38%  15% (range, 7%-70%) predicted mortality
(Table 1).
Two thirds of patients had an ECMO device implanted in
the operating room. The ECMO circuit consisted of
a centrifugal pump (Tandem Heart, Cardiac Assist Inc,
Pittsburgh, Pa; Centrimag, Thoratec, Pleasanton, Calif;
CardioHelp, Maquet, Wayne, NJ) and a Quadrox oxygena-
tor (Maquet). A dual-stage femoral venous cannula (Estech,
San Ramon, Calif) was used for venous inflow. We pre-
ferred to use the axillary artery for arterial outflow, using
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anastomosed end-to-side to the axillary artery.
Depending on the residual cardiac function and body sur-
face area, we found that ECMO flows of 2.5 to 4.0 L/min
generally achieved adequate tissue perfusion. The IABP
or Impella device was left in situ to help offload the left ven-
tricle and offset the increase in afterload produced by
ECMO. Heparin was administered to a target activated clot-
ting time of 200 to 240 seconds. The mean duration of
support was 9.0  7.5 days (range, 1-25 days). Echocardi-
ography was used to assess left ventricular recovery and
guide ECMO weaning and explantation. One patient devel-
oped acute leg ischemia, requiring conversion from femoral
to axillary artery perfusion, but no other vascular complica-
tions developed.
Five patients died, for a 30-day mortality of 24%
(Table 2). Of the 5 patients who died, 4 had had previous
cardiac arrest, and in 2 of these cases, the cause wasery c March 2013
TABLE 2. ECMO implantation and outcomes data (n ¼ 21)
Variable Value
Implant data
Location of ECMO implant:
Catheterization laboratory 7 (33%)
Operating room 14 (67%)
Site of arterial outflow
Percutaneous femoral (all placed in catheterization
laboratory)
7 (33%)
Axillary (all placed in operating room) 14 (67%)
Duration of support (d) 9.0  7.5
Outcomes
30-day all-cause mortality 5 (24%)
30-day mortality by location of ECMO implant:
Catheterization laboratory 4/7 (57%)
Operating room 1/14 (7%)
ECMO as bridge
Recovery 9 (43%)
CABG 5 (24%)
LVAD/transplantation 2 (10%)
Prolonged ventilation 10 (48%)
Pneumonia 3 (14%)
Renal failure 1 (5%)
Stroke 1 (5%)
Irreversible neurologic injury 2 (10%)
Multiorgan failure 1 (5%)
Bleeding 2 (10%)
Vascular injury 0 (0%)
Septicemia 3 (14%)
Data presented as n (%) or mean standard deviation. ECMO, Extracorporeal mem-
brane oxygenation; CABG, coronary artery bypass grafting; LVAD, left ventricular
assist device.
Case Reportsirreversible neurologic or multiorgan injury. One patient
died of persistent hypoxia and acidosis failing resuscitation,
and one died of refractory shock and cardiac arrest despite
ECMO and IABP therapy. Sixteen patients survived, all of
whom were discharged: 11 patients were weaned off
ECMO, 3 underwent coronary artery bypass grafting, and
2 underwent left ventricular assist device implantation
and subsequent cardiac transplantation.
DISCUSSION
Myocardial infarction with cardiogenic shock still carries
a staggering 40%mortality, with or without IABP support.1
We hypothesized that peripheral, mechanical circulatory
support with VA ECMO might yield better survival byThe Journal of Thoracic and Caaugmenting systemic perfusion, allowing recovery or pro-
viding a bridge to an implantable left ventricular assist de-
vice or transplantation. An additional advantage of pECMO
is that it can be rapidly deployed and, in contrast to a periph-
eral left ventricular assist device, such as the Tandem Heart
(Cardiac Assist), does not require trans-septal puncture. Our
experience has shown that in most patients, VA ECMO
effected a rapid reversal of the metabolic sequelae of shock,
with normalization of the arterial blood gases and lactate
level and an improvement in renal and hepatic func-
tion within 12 to 24 hours. However, those with irrevers-
ible neurologic injury, multiorgan failure, or persistent
metabolic acidosis, regardless of where the pECMO
implantation took place (operating room or catheterization
laboratory), had a poor prognosis.
One potential limitation in this approach was inadequate
decompression of the left ventricle to allow for myocardial
recovery. With a combination of pECMO, IABP, and low-
dose inotropic support, we did not observe left ventricular
distension and resultant pulmonary edema among our pa-
tients. However, a pulmonary artery vent or balloon atrial
septostomy could be potential options to address this issue.2
The observed 30-day mortality of 24% was a substantial
improvement over the published results1 and the Acute
Physiology and Chronic Health Evaluation IV predicted
mortality of 38% for this group. Along with other recent re-
ports,3,4 this experience suggests that pECMO might be
a better management option for cardiogenic shock
complicating acute myocardial infarction.
We would like to thank Lisa Vanderbeek and Cindy Yu for their
assistance in this study.
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